NASDAQ: ENSG · Medical Care Facilities
Ensign Group (ENSG) fair value: undervalued or overvalued?
As of 2 Oct 2026, Faircurve's model values Ensign Group (ENSG) at $148.78 a share. The stock last closed at $171.78, which puts the model's fair value 13.4% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. The Ensign Group, Inc.
Faircurve Insights · 2 Oct 2026
The Ensign Group, Inc. operates as a healthcare provider, primarily concentrating on post-acute care services, alongside other supporting business ventures. The company's activities are organized into two main divisions: Skilled Services and Real Estate.
Faircurve's model valued The Ensign Group, Inc. on 2 Oct 2026 at $148.78 a share, the midpoint of 2,000 simulations. The previous run on 26 Sep 2026 gave $155.96, so the fair value moved -4.6%. The calibrated range over 63 trading days is $124.82 to $181.41, built from the fair value since there is no live options data for the stock, calibrated weekly against realised prices (4,327 past valuations, refreshed 26 Sep 2026); ranges built this way held the price 60% of the time at this horizon. The model's evidence grade is Medium.
The overall quality score is 52 out of 100 against comparable companies. The model compares the company with Universal Health Services, Inc., DaVita Inc., Encompass Health Corporation, Hims & Hers Health, Inc., Tenet Healthcare Corporation, Concentra Group Holdings Parent, Inc., and National HealthCare Corporation. The stock has moved by a median size of 6.2%, ignoring direction, around its last 8 earnings reports.
Written from the figures on this page for the 2 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give ENSG?
The calibrated range for ENSG over 63 trading days is $124.82 to $181.41. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $114.23 to $190.43. In 32% of the simulations the fair value came out above the price the model ran on.
How does ENSG score on business quality?
Ensign Group's overall quality score is 52 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 15 | 8.0%ROIC | 12.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 59 | 1.11xFCF / net income | 1.18x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 87 | 18.7%Revenue growth, trailing | 10.5% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 55 | 0.4%Net buybacks / market value | 1.3% |
| Balance sheetNet debt to EBITDA and interest coverage. | 44 | 3.20xNet debt / EBITDA | 1.96x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 85 | 0.8 ptsEBITDA margin downside volatility, 5y | 1.2 pts |
How does ENSG compare with similar companies?
The companies in medical care facilities closest to Ensign Group in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| UHS Universal Health Services, Inc. | $175.72 | $255.94 | +45.7% | Undervalued |
| DVA DaVita Inc. | $178.69 | $230.01 | +28.7% | Undervalued |
| EHC Encompass Health Corporation | $119.80 | $119.78 | 0.0% | Fairly valued |
| CHE Chemed Corporation | $507.50 | $507.32 | 0.0% | Low evidence grade |
| HIMS Hims & Hers Health, Inc. | $29.00 | $29.24 | +0.8% | Fairly valued |
| THC Tenet Healthcare Corporation | $258.62 | $293.18 | +13.4% | Fairly valued |
| CON Concentra Group Holdings Parent, Inc. | $35.65 | $38.11 | +6.9% | Fairly valued |
| NHC National HealthCare Corporation | $227.66 | $263.84 | +15.9% | Undervalued |
All medical care facilities stocks ranked by gap to fair value
When does ENSG report earnings, and how has the stock reacted?
Ensign Group's next earnings report is scheduled for 2 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 4.4% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction.
How ENSG moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 6.2%.
| Report date | Two session move |
|---|---|
| 27 Jul 2026 | +5.9% |
| 30 Apr 2026 | -1.4% |
| 4 Feb 2026 | +13.6% |
| 3 Nov 2025 | +2.2% |
| 24 Jul 2025 | +7.8% |
| 29 Apr 2025 | +20.9% |
| 5 Feb 2025 | -6.5% |
| 24 Oct 2024 | +1.9% |
Ensign Group at a glance
The Ensign Group, Inc. operates as a healthcare provider, primarily concentrating on post-acute care services, alongside other supporting business ventures. The company's activities are organized into two main divisions: Skilled Services and Real Estate.
- Market value
- $10.2B
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Revenue expected, next twelve months
- $6.4B
- Consensus revenue growth, next fiscal year
- +16.7%
- Analysts with estimates
- 3
- Beta to the US market
- -0.11
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Ensign Group on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for ENSG was $155.96. As of 2 Oct 2026 it is $148.78, a change of -4.6%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Ensign Group's valuation
Is Ensign Group stock undervalued or overvalued?
On Faircurve's model, ENSG reads as Fairly valued as of 2 Oct 2026. The model's fair value is $148.78 a share against a last close of $171.78, a gap of -13.4%.
What is ENSG's fair value?
$148.78 a share as of 2 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $114.23 to $190.43.
What price range does the model give ENSG?
$124.82 to $181.41 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Ensign Group report earnings next?
The next report is scheduled for 2 Nov 2026. Companies can move their dates.
How much has ENSG moved on past earnings reports?
Across its last 8 reports the median two session move was 6.2%, ignoring direction. The largest was +20.9% around the report of 29 Apr 2025.
How confident is the model in this valuation?
The model's evidence grade for ENSG is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.